Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

Key Inclusion Criteria:

• Eligible subjects are those subjects who complete study BHV4157-302 or BHV4157-303and for whom the investigator believes open-label treatment offers an acceptablerisk-benefit profile.

• Determined by the investigator to be medically stable at the week 10 visit ofBHV4157-302 or BHV4157-303, as assessed by medical history, physical examination,laboratory test results, and electrocardiogram testing.

• It is required that all women of child-bearing potential (WOCBP) who are sexuallyactive agree to use two methods of contraception for the duration of the study

Key Exclusion Criteria:

• Subjects who did not successfully complete 10 weeks of treatment in the BHV4157-302or BHV4157-303 study.

• Acute suicidality or suicide attempt or self injurious behavior in the last 12months.

• Patients who may have received a non-biological investigational agent in anyclinical trial within 30 days or a biological agent within 90 days prior to entry,other than what was received in BHV4157-302 or BHV4157-303;